Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - March 23, 2026) - Doubleview Gold Corp. (TSXV: DBG) (OTCQB: DBLVF) (FSE: 1D4) ("Doubleview" or the "Company") provides clarification to its news release dated March 2, 2026, announcing the Preliminary Economic Assessment ("PEA") for the Company's 100% owned Hat Project in northwestern British Columbia.Following publication of the March 2, 2026 news release, Mineit Consulting Inc., the independent engineering firm responsible for the PEA, completed a further review of the application of certain processing cost assumptions relating to the scandium recovery circuit in Scenario B. As a result of this review, the after-tax NPV(5%) for Scenario B at consensus metal prices has been updated to C$7.27 billion from C$6.94 billion and IRR of 19%. The update also results in an increase in Scenario B after-tax NPV(5%) at spot metal prices to C$14.85 billion from C$14.52 billion and IRR of 32%.The updated Scenario B results further demonstrate the economic contribution of the scandium recovery circuit and increase the difference in after-tax NPV between the base case (Scenario A2) and Scenario B to C$547 million.The cobalt grade reported in Table 1 of the Company's March 2, 2026 news release was inadvertently shown as 0.78 g/t Co. The correct value is 78 g/t Co, consistent with Table 5 of the release. This discrepancy was limited to the summary table presentation and does not affect the PEA results or conclusions.These clarifications do not change the overall conclusions of the PEA and further highlight the strong economics of the Hat Project, including the potential value contribution from scandium recovery.Corrected highlights of the PEA reflecting the updated Scenario B economics are presented below.NPV:After-tax NPV(5%) of C$6.73 billion and IRR of 23% at Consensus Metal Prices After-tax NPV(5%) of C$13.53 billion and IRR of 39% at Spot Metal PricesNPV Including scandium and the associated processing circuit: After-tax NPV(5%) of C$7.27 billion and IRR of 19% at Consensus Metal PricesAfter-tax NPV(5%) of C$14.85 billion and IRR of 32% at Spot Metal PricesThree processing scenarios were evaluated-Scenario A1 (A1) a Cu-Au-Ag-Co flotation base case using current testwork recoveries1, Scenario A2 (A2), the same base case using expected recoveries1, and Scenario B (B), a Cu-Au-Ag-Co flowsheet with an added hydrometallurgical circuit and scandium recovery circuit, with results indicating the Project is financially attractive even without the scandium component.Highlights:Robust Project Economics: The PEA demonstrates a high-margin operation with an After-Tax NPV(5%) of C$4.96 billion (A1), C$6.73 billion (A2), or C$7.27 billion (B), and an IRR of 19% (A1), 23% (A2), or 19% (B) at analyst consensus metal prices2. Using a spot-price scenario3, the Project delivers a compelling after-tax NPV(5%) of C$11.05 billion (A1), 13.53 billion (A2), or C$14.85 billion (B) and an IRR of 34% (A1), 39% (A2), or 32% (B).Sensitivity Highlight: Project economics show the greatest leverage to overall metal prices, with NPV (5%) ranging from C$3.2 billion to C$10.2 billion (IRR: 14%-32%) at ±20% on all metals; even under additional +20% CAPEX and +20% OPEX sensitivities, applied on top of a 25% contingency already embedded in the base case, all scenarios deliver IRRs of 16% or better, and Scenario B provides additional scandium oxide upside with NPV(5%) of C$6.5 billion-C$8.1 billion (IRR: 18%-20%) at ±40% metal price.Scale and Longevity: The mine plan supports a multi-decade life of 25 years at a 120,000 tonnes-per-day processing rate, underpinned by a resource base of 609 Mt at 0.43% CuEq4 in the Measured and Indicated categories and 503 Mt at 0.41% CuEq4 in the Inferred category.High-Output Production Profile B: Envisioned as a conventional large-scale open-pit operation, the Project is expected to produce an average of over 74 kt of copper, 254 koz of gold, 376 koz of silver and 2.7 kt of cobalt annually during the first 10 years, with life-of-mine (LOM) average production of 67.6 kt Cu, 217 koz Au, 348 koz Ag, 2.5 kt Co, and 128 tonnes of scandium oxide per year. (NOTE: based on publicly reported 2024 North American cobalt mine production of approximately 3,800-4,000 tonnes (Natural Resources Canada; U.S. Geological Survey), the projected cobalt output is estimated to represent approximately 69% of current regional mined supply).Strategic Importance for Critical Minerals: The Project is positioned as a primary North American source of copper, scandium, and cobalt. With approximately 2.42 billion pounds of copper, 80 million pounds of cobalt and 2,415 tonnes of scandium oxide contained5 in the Measured and Indicated categories, the Project represents an important discovery of critical minerals.Stable, Supportive Jurisdiction: Located in a premier mining district in British Columbia, the Project benefits from a stable regulatory environment. The Company is committed to engaging with local First Nations in a respectful manner and to working toward positive and constructive relationships as the Project advances.Catalyst for Development: The PEA serves as the technical foundation for an immediate transition into a Pre-Feasibility Study (PFS), providing a clear roadmap for early works and permitting activities in 2026 and 2027.Farshad Shirvani, President and CEO of Doubleview Gold Corp., commented, "The results of this PEA confirm the scale, strength and long-term potential of the Hat Project. Delivering a post-tax NPV(5%) of up to C$6.73 billion and IRR of up to 23% at consensus prices, and even stronger metrics at spot prices, validates years of disciplined exploration and technical work by our team. Hat is demonstrating Tier 1 characteristics with a 25-year mine life, strong annual production profile and meaningful free cash flow generation. Importantly, the Project stands on its own without reliance on scandium, while still preserving significant upside from critical minerals as markets mature. We are excited to advance Hat to Pre-Feasibility and continue building a major Canadian critical metals project."Doubleview acknowledges that the Project is located on the traditional territories of the Tahltan Nation and the Taku River Tlingit First Nation, and recognizes their enduring relationship to and stewardship of the land and waters. Doubleview is committed to respectful, transparent, and ongoing engagement with First Nations and local communities whose territories overlap the Project area and access routes, with a focus on protecting water and the environment and advancing responsible development.PEA OVERVIEWThe PEA contemplates a conventional open-pit mine and processing operation with a 25-year mine life at a 120,000 t/d (42 Mt/a) plant throughput. Two processing pathways were evaluated, A1 and its alternative, A2, and B: the first alternative, A, is a Cu-Au-Ag-Co flotation concentrator with two recovery cases based on current metallurgical testwork, and A2, reflecting expected performance (Figure 1); and B, a full circuit that retains the base flowsheet and adds a downstream hydrometallurgical scandium recovery circuit (Figure 2).The tailings storage facility is a centreline-raised facility built with compacted cycloned sand from tailings underflow, and engineered drainage for stability, with site-contact waters (including seepage and pit dewatering) recycled to the process plant and final closure involving pond drainage and reclamation. The Project is expected to rely on grid power via an extended transmission line.Tables 1 to 3 summarize the key results of the PEA, including production, operating costs, capital expenditures, and the principal financial metrics; the sections that follow provide additional detail on the underlying assumptions, project design, and study outcomes.Table 1: PEA Study Summary-ProductionMetric UnitScenario A1Scenario A2Scenario BMining SummaryStrip ratiot:t1.60Production Summary LOMAverage Annual ThroughputMt42CuEq Head Grade6, 7%0.42Cu Head Grade%0.19Au Head Gradeg/t0.19Ag Head Gradeg/t0.51Co Head Gradeg/t77.73Sc Head Grade6g/t28.35Cu Recovery%8089858Au Recovery%6675898Ag Recovery%5353688Co Recovery%3030788Sc Recovery%N/A728Overall Mass of Tailings to Process9%N/A12.5Year of Production Start of Sc2O38yearN/A4Average Annual Cu Productionkt63.670.867.6Total Cu Productionkt1,590.51,769.41,689.9Average Annual Payable Cukt61.768.765.7Total Payable Cukt1,542.81,716.31,642.2Average Annual Au Productionkoz161.1183.1217.3Total Au Productionkoz4,028.24,577.55,432.0Average Annual Payable Aukoz153.1173.9207.5Total Payable Aukoz3,826.84,348.75,188.6Average Annual Ag Productionkoz271.3271.3348.0Total Ag Productionkoz6781.66,781.68,700.9Average Annual Payable Agkoz244.1244.1318.6Total Payable Agkoz6,103.46,103.47,965.3Average Annual Co Productionkt1.01.02.5Total Co Productionkt23.923.962.2Average Annual Payable Cokt0.80.82.3Total Payable Cokt19.119.156.3Average Annual Sc2O3 ProductiontN/A128.4Total Sc2O3 ProductiontN/A3,209.5Total Sc2O3 PayabletN/A3,049.0 Table 2: PEA Study Summary-Operating CostMetricUnitScenario A1Scenario A2Scenario BOperating Cost Average Mine Operating CostsC$/t-moved2.32Average Mine Operating CostsC$/t-milled6.03Processing Operating Cost10C$/t-milled7.937.9310.84Sc2O3 Processing Cost11C$/kg Sc2O3N/A939.55General & AdministrativeC$/t-milled2.562.562.56Total Operating CostsC$/t-milled16.2216.2221.92 Table 3: PEA Study Summary-Capital Expenditure and Financial MetricsMetricUnitScenario A1Scenario A2Scenario BCapital Expenditure Initial Capital CostsC$M3,5523,6013,828Sustaining Capital CostsC$M2,7552,7554,006Closure and Reclamation CostC$M503Financial Metrics Exchange RateCAD/USD1.37Long Term Copper PriceUS$/lb4.88Long Term Gold PriceUS$/oz3,272.60Long Term Silver PriceUS$/oz50.22Long Term Cobalt PriceUS$/lb19.57Long Term Scandium Oxide PriceUS$/kgN/A1,500Average Annual EBITDAC$M8861,0711,284Total EBITDAC$M22,16226,77032,101Average Annual Free Cash Flow (Pre-tax)C$M7569401,104Free Cash Flow (Pre-tax)12C$M18,90423,51127,592Total Provincial Tax (inc. BC Mineral Tax)C$M(4,029)(5,090)(6,019)Total Federal TaxC$M(1,274)(1,859)(2,308)Total TaxesC$M(5,303)(6,949)(8,327)Average Annual Free Cash Flow (Post-tax)C$M544662771Free Cash Flow (Post-tax)12C$M13,60116,56219,265Total Free Cash Flow (Pre-tax)13C$M15,35219,91023,764Total Free Cash Flow (Post-tax)12C$M10,05012,96115,437NPV 5% (Pre-tax)C$M7,88310,57611,567NPV 5% (Pre-tax)US$M5,7547,7208,443IRR (Pre-tax)%242923Payback (Pre-tax)yearsYear 5Year 4Year 6NPV 5% (Post-tax)C$M4,9636,7277,274NPV 5% (Post-tax)US$M3,6234,9115,309IRR (Post-tax)%192319Payback (Post-tax)YearsYear 6Year 5Year 7 Table 4 shows the Sensitivity analysis using after-tax NPV(5%) and after-tax IRR.Table 4: Sensitivity AnalysisVariableCase(%)Metal PriceScenario A1Scenario A2Scenario BNPV (5%) C$MIRR(%)NPV (5%)C$MIRR(%)NPV (5%)C$MIRR(%)Base Case Consensus forecast4,963196,727237,27419Copper Price-20US$3.90/lb Cu3,218154,807195,43316Copper Price+20US$5.86/lb Cu6,688238,632289,09922Gold Price-20US$2,618.08/oz3,625165,223195,53916Gold Price+20US$3,927.12/oz6,289228,222278,99622Metal Prices-20All metal prices1,708103,165142,99311Metal Prices+20All metal prices8,1182710,2333211,44426Initial CAPEX+20Variable per Scenario4,448166,222196,73216OPEX+20Variable per Scenario3,660165,438205,59116Scandium Oxide Price-40US$900/kg Sc2O3 6,49618Scandium Oxide Price+40US$2,100/kg Sc2O3 8,05020 MINERAL RESOURCE ESTIMATEDoubleview Gold Corp announced an update of the Mineral Resource estimate (MRE). This estimate followed the Micon International Ltd. (Micon) Mineral Resource estimate with an effective date of July 17, 2024. This MRE incorporates significant new data from the 2024 and 2025 exploration campaigns, with an effective date of February 4, 2026, and superseded the 2024 Micon estimate.Table 5: Hat MRE at a 0.2% CuEq Cut-Off Effective February 4, 2026Mineral Resource ClassificationTonnage(Mt)Average GradeMetal ContentCuEq(%)Cu(%)Au(g/t)Co(g/t)Ag(g/t)CuEq(Blb)Cu(Blb)Au(Moz)Co(Mlb)Ag(Moz)Measured2720.440.220.1876.260.372.611.111.4135.62.17Indicated3370.430.210.1976.810.393.211.311.8144.52.88Total M+I6090.430.210.1876.570.385.822.423.2280.15.05Inferred5030.410.180.1976.620.384.571.722.7766.24.19 Table 6: Hat MRE at a 0.2% CuEq Cut-Off as of February 4, 2026, Scandium Oxide ResourcesMineral Resource ClassificationTonnage(Mt)Sc Tonnage1(Mt)Average GradeSc (g/t)Metal ContentSc2O3 2 (t)Measured2723428.791,081Indicated3374228.761,334Total M+I6097628.772,415Inferred5036328.691,996 Notes: 1 Scandium tonnages represent 12.5% of the mineralized material by category, reflecting the proportion of tailings expected to be processed through a dedicated scandium leach circuit under current metallurgical design constraints.2 Scandium oxide metal content have been calculated using the metallurgical recovery of 72% and conversion factor from Sc to Sc2O3 of 1.534. Mineit's Qualified Person, Tomasz Wawruch, FAusIMM, completed the MRE, and has reviewed and approved the technical disclosure related to the MRE contained in this news release. Mr. Wawruch is a senior geology and mineral resource consultant independent of Doubleview. Mr. Gilles Arseneau, PhD., P.Geo., of ARSENEAU Consulting Services Inc., provided an independent review of this MRE.Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability.The estimate of Mineral Resources may be materially affected by environmental, permitting, legal, title, taxation, socio-political, marketing, or other relevant issues.Inferred Mineral Resources are considered too speculative geologically to have economic considerations applied to them that would enable them to be categorized as Mineral Reserves. The Mineral Resource Estimate was prepared in accordance with the Canadian Institute of Mining, Metallurgy and Petroleum (CIM) Definition Standards for Mineral Resources and Mineral Reserves (2014), and CIM MRMR Best Practice Guidelines (2019).The effective date of the MRE is February 4, 2026.Metal contents have been calculated using the following metallurgical recovery factors: Cu = 85%, Au = 89%, Co = 78%, and Ag = 68%.Economic assumptions used include US4.80/lb Cu, US20.00/lb Co, US3,200/oz Au, US46/oz Ag, and a 2% NSR royalty.Mineral Resources are reported within optimized open pit constraints and 0.2% CuEq cut-off grade, based on a C7.93/t milled processing cost and C2.90/t milled general and administrative cost, with a mining cost of C3.01/t plus incremental mining cost increasing by C0.015/t for every bench below the reference level of 1,125 mRL.CuEq calculations do not include scandium. The formula used to calculate CuEq is: CuEq = [(((Ag × 46.0 × 0.68)/31.1035) + ((Au × 3200 × 0.89)/31.1035) + 0.0001 × (Co × 20.0 × 0.78 × 22.0462) + 0.0001 × (Cu × 4.8 × 22.0462 × 0.85))/(4.8 × 22.0462 × 0.85)], where all input variables are expressed in (ppm) and CuEq is expressed in percent (%).Rounding may result in minor variations between individual values and totals; such differences are not considered material to the MRE.Mineral Resource classification reflects the level of geological confidence and satisfies the uncertainty criteria appropriate for exploration and resource development. Additional drilling will be required to reduce uncertainty to the level expected for production planning. The MRE reflects the geological interpretation, drill-hole spacing, and estimation parameters available at the time of modelling. Any additional drilling is expected to influence the current outcome by improving confidence in the estimates and refining the geometry of the mineralized domains.The Mineral Resource results are presented in situ within the optimized pit. Mineralized material outside the pit has not been considered as a part of the current MRE tabulation. Calculations used metric units (metres, tonnes, g/t).A total of 97 diamond drill holes, comprising 49,548 m of core, were incorporated into the Mineral Resource Estimate. All drilling data used in the MRE were subject to standard QA/QC validation prior to inclusion.PROCESSING SCENARIOSThe PEA evaluates two processing scenarios: (A) a conventional Cu-Au-Ag-Co flotation concentrator at 120,000 t/d (42 Mt/a) with two recovery cases-A1 based on metallurgical testwork completed by Sepro Laboratories (Langley, BC) and A2 reflecting target/expected performance-and (B) a full circuit that retains the base flowsheet and adds a downstream hydrometallurgical scandium recovery circuit.The concentrator consists of crushing, grinding, flotation, concentrate handling, and tailings management, producing both a saleable approximately 25% Cu concentrate with co-product gold and by-product silver-cobalt credits and a pyrite concentrate enriched in cobalt; in the full-circuit case, the pyrite concentrate is roasted to generate sulphuric acid and a calcine that is then processed to recover cobalt, gold, silver, and copper; after stripping it will be precipitated as a sulphide to be admixed to the copper concentrate to improve grade, with the acid used to leach flotation tailings for scandium recovery, noting that the scandium circuit is a newer chemical process compared with the otherwise industry-standard flowsheet.Under A1 or A2 (Figure 1), the flowsheet produces a single saleable product-a copper concentrate with payable gold credits; the pyrite concentrate is not treated or marketed in this case and is only processed in B where the hydrometallurgical circuit enables recovery of cobalt (and additional Au-Ag) and supports the scandium circuit (Figure 2), which is planned to be constructed in a phased approach commencing in Year 3 of operations.Figure 1: Grinding and Flotation Flowsheet; Scenarios A1/A2 Report Copper Concentrate Only, while the Cobalt-Pyrite Flotation Stream Shown Is Included Only in Scenario BTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/289584_doubleview1.jpgFigure 2: Scenario B Hydrometallurgical Plant Block Flow Diagram, Showing Downstream Treatment of the Cobalt-Pyrite Stream and Flotation of Tailings to Recover Cobalt (and Au-Ag) and Scandium, Including Sulphuric Acid Generation to Support the Scandium CircuitTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/289584_94c53b19649fcaba_003full.jpgTable 7 summarizes the head grades, concentrate grades, and overall metallurgical recoveries from early testwork for the full circuit; A1 assumes only the reported recoveries to the Cu-Au concentrate, while the cobalt-pyrite concentrate and downstream recoveries are considered only in B.Early metallurgical testwork comprised metallurgical characterization studies under standard laboratory conditions to demonstrate metals recoverability for inclusion in the estimate of CuEq. No attempt was made to optimize flotation conditions, and more advanced flotation testwork was not undertaken. Consequently, the reported metallurgical recoveries are considered conservative, and it is reasonable to expect improvement with further testwork.A2, assumes improved copper and gold recoveries of 89% and 75%, respectively, reflecting expected performance from comparable Cu-Au porphyry flotation circuits following further optimization and testwork.Table 8 summarizes the recoveries assumption on each scenario.CAPITAL COST SUMMARYTable 9 presents the estimated capital cost breakdown for the three evaluated scenarios, separating initial CAPEX from sustaining CAPEX and reporting costs in C$M by major cost area (processing plant, mining, pre-stripping, infrastructure, tailings and water management, Indirects/EPCM, and contingency).Total initial CAPEX is estimated at C$3,552 million (A1), C$3,601 million (A2), and C$3,828 million (B), reflecting the higher processing plant scope and associated indirects/contingency in Scenario B.Total sustaining CAPEX is estimated at C$2,755 million (A1/A2) and C$4,006 million (B), with the increase in B driven primarily by the inclusion of the hydrometallurgical plant and scandium recovery circuit within sustaining capital, while mining, infrastructure, and tailings sustaining components remain broadly consistent across scenarios.OPERATING COST SUMMARYTable 10 summarizes the key operating cost and selling terms used in the PEA, reporting unit costs in C$/t moved, C$/t milled, and (where applicable) C$/kg of scandium oxide, together with concentrate transport and selling costs, TC/RC, and payability assumptions.Average site operating costs are estimated at C$16.22/t milled for Scenario A (concentrate-only) and C$21.92/t milled for B, with the increase in B driven by the addition of hydrometallurgical processing and acid generation (C$3.09/t milled) and scandium oxide processing costs (C$939.55/kg Sc₂O₃).On a payable metal basis, the study reports C1 cash costs of C$2.4/lb CuEq (A1), C$2.39/lb CuEq (A2), and C$2.89/lb CuEq (B) and AISC of C$2.79/lb CuEq (A1), C$2.78/lb CuEq (A2), and C$3.39/lb CuEq (B), reflecting the combined effects of recoveries, co-product/by-product credits, and the additional operating requirements of the full circuit.ECONOMIC RESULTSTable 11 summarizes the key economic assumptions and resulting financial metrics for Scenarios A1, A2, B, including the long-term price deck, cash flow generation, taxation, and discounted valuation at a 5% discount rate. Using an exchange rate of 1.37 CAD: 1.00 USD and long-term prices of US$4.88/lb Cu, US$3,272.60/oz Au, US$50.22/oz Ag, and US$19.57/lb Co (and US$1,500/kg Sc₂O₃ for B), the Project generates average annual EBITDA of C$886 million (A1), C$1,071 million (A2), and C$1,284 million (B). On a post-tax basis, NPV(5%) is estimated at C$4,963 million (A1), C$6,727 million (A2), and C$7,274 million (B) with corresponding post-tax IRRs of 19%, 23%, and 19%, and post-tax payback in Year 6 (A1), Year 5 (A2), and Year 7 (B). Total post-tax free cash flow is estimated at C$10,050 million (A1), C$12,961 million (A2), and C$15,437 million (B), reflecting the higher cash generation under the improved recovery case (A2) and the additional revenue streams in Scenario B, partially offset by the added capital and operating requirements of the hydrometallurgical and scandium circuits.SENSITIVITY ANALYSISSensitivity cases were evaluated for the key value drivers using after-tax NPV (5%) and after-tax IRR, including ±20% copper and gold prices, +20% initial capital, +20% operating costs and, for B, a ±40% scandium price sensitivity.Overall, the sensitivity analysis demonstrates that the Project's after-tax economics remain positive across the tested ranges, with the greatest variability in after-tax NPV(5%) and IRR driven by simultaneous changes in the overall metal price deck. Changes to copper and gold prices individually have a meaningful but smaller effect, while +20% initial CAPEX and +20% OPEX reduce value but do not eliminate Project attractiveness in any of the evaluated scenarios. Scenario B shows additional exposure to scandium oxide price, with after-tax NPV(5%) varying within a narrower range relative to the broader multi-metal price cases, indicating that scandium provides incremental upside while the base-case Cu-Au Project remains financially robust on its own.PERMITTING, RISKS, AND NEXT STEPSPermitting and EnvironmentalPermitting StatusThe permitting process will be supported by the continuation of environmental baseline studies, progression of engineering designs, and the initiation of socio-economic and cultural baseline studies.Due to the anticipated rate of resource extraction, it is expected that the Hat Project will be subject to both federal and provincial impact assessment pathways, so submission to both the Impact Assessment Agency of Canada (IAAC) and British Columbia Environmental Assessment Office (B.C. EAO) for their review is currently anticipated. Agency determination will decide the appropriate level of agency collaboration under the existing cooperation agreement for the Hat Project to acquire a provincial Environmental Assessment Certificate (EAC) and/or federal Decision Statement.The company will also submit a Joint Mines Act and Environmental Management Act Application through the B.C. Major Mines Office. Additional federal authorizations, including Fisheries Act approvals and compliance with Metal and Diamond Mines Effluent Regulations (MDMER), and applicable provincial permits will be obtained concurrently with other assessment and permitting steps. This will not only support protection of the immediate environment through the life of the Project but also respect the rights of First Nations and promote social and economic wellbeing for local communities.Tailings and Water ManagementThe Tailings Storage Facility (TSF) includes a perimeter dyke primarily constructed from compacted cycloned sand. This material will be sourced from the coarse underflow of tailings processed through an on-site cyclone plant. Using the centreline raise method, the dam is designed to be free-draining, lowering the phreatic surface to facilitate geotechnical stability. During operations, seepage from the TSF will be directed to the process plant as reclaim water. Upon closure, the supernatant pond will be drained, and the tailings and dam surfaces will be reclaimed with a granular trafficability layer, followed by a growth medium and native revegetation.The water management strategy prioritizes the reuse of site-impacted water, directing TSF water, contact water from the waste rock storage facilities, and open-pit dewatering to the process plant for use as make-up water.Key Risks and OpportunitiesProject-wideTailings Storage Facility:The location and geometry of the TSF are subject to refinement following geotechnical investigations of the potential site areas. Similarly, the anticipated availability of cycloned sand and the storage requirements for the facility may be adjusted once laboratory testing of the tailings is conducted.The integration of this future site-specific data presents a significant opportunity to optimize the TSF design.Mineral Processing:Limited metallurgical and comminution data introduce uncertainty in equipment sizing and operating cost inputs; however, early results indicate the ore should be amenable to conventional Cu-Au flotation, with potential upside from improved recoveries and reduced reagent consumption through optimization.The scandium circuit is less mature and is sensitive to acid economics and hydrometallurgical performance, but offers meaningful value upside if recoveries, product quality, and operating stability are confirmed at larger scale.Mine Design:Pit slope design criteria and mine scheduling are subject to elevated uncertainty due to the limited geotechnical database, including incomplete definition of structural controls, rock mass variability, and groundwater conditions. This creates downside risk to slope angles, strip ratio, and operating conditions if adverse structures or hydrogeology are encountered; however, it also provides a clear opportunity to materially improve design confidence and potentially optimize slope geometry, mine sequencing, and dewatering requirements through focused data acquisition and updated analyses.Capital Cost estimates:As a PEA-level estimate, capital costs remain subject to the inherent uncertainty of a preliminary design basis and limited engineering definition; however, significant effort was undertaken to develop the estimate using a defined scope, preliminary equipment sizing, and factored/benchmark-based costing with appropriate indirects and contingency. This work provides a credible foundation for decision-making at this stage while also highlighting clear opportunities to optimize capital intensity through further engineering definition, value engineering, and targeted trade-off studies (e.g., comminution configuration, tailings strategy, infrastructure/power, and construction execution approach).Scandium specific:Scandium provides strategic upside given its small, concentrated global supply base and the growing premium placed on secure, qualified supply, but it carries higher execution and commercial risk due to limited scale-up testwork (variability, impurity control, reagent intensity), added residue-management and permitting complexity, and uncertainty around product specifications, pricing, and customer qualification.Next StepsResource:The Company is advancing the Project toward Pre-Feasibility by upgrading confidence in the current Mineral Resource estimate and improving definition of mineralization within the proposed mine plan area. The program will prioritize infill drilling to support conversion of Inferred Resources to Indicated (and, where appropriate, Measured), together with step-out drilling to test extensions of known mineralization and provide improved geological continuity for next-stage mine design, scheduling, and economic evaluation.Waste facilities:Field investigations will be conducted at potential TSF and waste rock storage sites to characterize subsurface conditions and identify suitable borrow materials for construction. These efforts will be supported by site-specific geotechnical and geochemical characterization of the tailings and waste rock. These data sets will inform a TSF design update to a Pre-Feasibility Study (PFS) level of engineering, encompassing an optimized siting and technology trade-off study.Metallurgy:Complete a comprehensive metallurgical testwork program on representative samples including comminution testwork (Bond Work Index, abrasion index, and related grindability tests) and metallurgical variability + locked-cycle flotation testing to define an optimal process flowsheet, mass balance, and optimized reagent scheme, and to produce samples for concentrate dewatering and preliminary smelter marketing.Progress the scandium work through targeted hydrometallurgical optimization including pulp density, free acidity/acid consumption, SX staging and extractant concentration, followed by an integrated pilot trial on bulk samples to validate scandium recovery, product quality, and circuit operability.Mine Design:A phased geotechnical program is recommended that includes re-analysis of existing boreholes (re-logging and detailed structural mapping, including oriented-core interpretation where available), establishment of geotechnical domains, targeted drilling and field mapping to confirm discontinuity sets and persistence, and hydrogeological data collection to constrain pore pressures and inflows. These data will support updated kinematic assessments and slope design analyses, refinement of inter-ramp and overall slope angles, and improved inputs to mine planning, risk management measures, and capital/operating cost estimates.Capital Costs Estimation:As the Project advances to PFS, the estimate will be progressively refined by advancing engineering to a higher level of definition, updating quantities and vendor inputs for major equipment and packages, tightening indirects and construction productivity assumptions, and executing focused optimization and constructability reviews to reduce contingency and improve overall cost confidence.NI 43-101 DISCLOSURE, QUALIFIED PERSONS, AND CAUTIONARY STATEMENTSQualified PersonsThe scientific and technical information in this news release has been reviewed and approved by the following Qualified Persons, each with respect to the matters within their area of expertise, (as defined under NI 43-101):Tomasz Wawruch, FAusIMM, Senior Geology and Mineral Resource Consultant of Mineit Consulting Inc. (responsible for the Mineral Resource estimate).Andrew Carter, EUR ING, B.Sc., CEng., MIMMM (QMR), MSAIMM, SME, of Magister Metallurgy (responsible for metallurgical studies and recovery processes).Shervin Teymouri, P.Eng., Mining Engineer of Mineit Consulting Inc. (responsible for project management, mining engineering, capital and operating cost estimates, and financial analysis).Andre de Ruijter, P.Eng., of Mineit Consulting Inc, (process design, process capital and operating cost lead).Franky Li, P.Eng., of EMM Consulting Pty Ltd (responsible for tailings management and TSF design, tailings capital and operating cost).Jayesh Rami, P.Eng., Infrastructure Engineer of Sacre-Davey Engineering Inc. (responsible for project infrastructure).Qualified Person ReviewThe scientific and technical information contained in this news release has been reviewed and approved by Shervin Teymouri, P.Eng., a Qualified Person as defined under National Instrument 43-101. Mr. Teymouri is a mining engineer and is independent of the Company.Preliminary Economic Assessment Cautionary StatementThe Preliminary Economic Assessment (PEA) for the Hat Project is preliminary in nature and includes Inferred Mineral Resources that are considered too speculative geologically to have economic considerations applied to them that would enable them to be categorized as Mineral Reserves. Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability. The PEA provides a conceptual mine plan and is based on low-level technical and economic assessments that are insufficient to support an evaluation of the economic viability of the Project or to establish Mineral Reserves. There is no certainty that the results of the PEA will be realized. Further exploration and site-specific engineering studies are required before a higher level of confidence can be established for the Project's economics.The economic analysis in the PEA is based on several assumptions including, but not limited to, long-term metal prices, foreign exchange rates, metallurgical recoveries, and capital and operating cost estimates. These assumptions are subject to significant risks and uncertainties, and actual results may differ materially from those projected. Readers are cautioned not to place undue reliance on the PEA or the forward-looking information contained in this release.Forward-Looking InformationCertain of the statements made and information contained herein may constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Often, these forward-looking statements can be identified using words such as "anticipates," "believes," "continue," "estimates," "expects," "forecasts," "intends," "plans," "projected," or the negatives thereof or variations of such words and phrases. Forward-looking statements in this news release include, but are not limited to, statements with respect to: the results of the Preliminary Economic Assessment for the Hat Project; the estimation of mineral resources; anticipated annual production of copper, gold, cobalt, and scandium; the after-tax NPV and IRR of the Project; forecasted AISC and Total Cash Costs; estimated initial and sustaining capital costs; the timing of a Pre-Feasibility Study; the timeline for permitting milestones and construction decisions; planned early works and infrastructure upgrades; and the Company's ability to maintain strong community and First Nations partnerships.Forward-looking statements are based on a number of assumptions that management considers reasonable at the time they are made, including assumptions regarding: the future prices of copper, gold, cobalt, and scandium; foreign exchange rates; metallurgical recoveries; the cost of essential consumables; and the geopolitical and regulatory climate in British Columbia. However, such statements involve known and unknown risks and uncertainties which may cause actual results to differ materially. These risks include but are not limited to inaccurate estimation of mineral resources; volatility in metal prices; the results of future exploration and development activities; liquidity and financing risks; failure to obtain necessary permits; geotechnical conditions; and changes in applicable mining laws. The PEA is preliminary in nature and includes Inferred mineral resources that are considered too speculative geologically to have economic considerations applied to them that would enable them to be categorized as mineral reserves. Except as required by law, the Company undertakes no obligation to update or revise forward-looking information as conditions change.Non-GAAP Financial MeasuresThe Company has included certain performance measures in this news release that are not specified, defined, or determined under Generally Accepted Accounting Principles (GAAP). These non-GAAP measures are common in the mining industry but do not have standardized definitions and may not be comparable to similar measures presented by other issuers. Readers should not consider these measures in isolation or as a substitute for performance measures prepared in accordance with GAAP.Total Cash Costs: The Company calculates total cash costs as the sum of mining, processing, refining and transport, G&A, and royalty costs. Cash costs per unit are calculated by dividing the total cash costs by the payable Copper Equivalent (CuEq) units.All-In Sustaining Cost: AISC is a non-GAAP financial measure comprising of total cash costs, sustaining capital expenditures to support ongoing operations, and closure costs. AISC per unit is calculated by dividing the total all-in sustaining costs by the payable CuEq units.Sustaining Capital: This is a supplementary financial measure reflecting cash-basis expenditures expected to maintain operations and sustain production levels over the life of the mine.About Doubleview Gold Corp.Doubleview Gold Corp., a mineral resource exploration and development company based in Vancouver, British Columbia, Canada, is publicly traded on the TSX Venture Exchange (TSXV: DBG), the OTCQB (DBLVF), the Berlin Stock Exchange (GER: A1W038), and the Frankfurt Stock Exchange (1D4). Doubleview identifies, acquires, and finances precious and base metal exploration projects in North America, particularly in British Columbia. The Company increases shareholder value through the acquisition and exploration of quality gold, copper, cobalt, scandium, and silver properties-collectively critical minerals-and through the application of advanced, state-of-the-art exploration methods. Doubleview's portfolio of strategic properties provides diversification and mitigates investment risk.About Mineit Consulting Inc.Mineit Consulting Inc. (Mineit) is an independent mining engineering consulting company providing specialized expertise in project management, geological modelling, Mineral Resource estimation, mining engineering, metallurgical, and process engineering. Mineit led and prepared the Hat Project MRE and PEA, with assistance from other engineering firms, for the Hat Project in accordance with the Canadian Institute of Mining, Metallurgy and Petroleum (CIM) Definition Standards on Mineral Resources and Reserves.For further information, please contact:Doubleview Gold CorpVancouver, BCFarshad ShirvaniPresident & CEOInstitutional Line: (604) 607-5470T: (604) 678-9587E: corporate@doubleview.caNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.Certain of the statements made and information contained herein may constitute "forward-looking information." In particular references to the Mineral Resource Estimate and future work programs or expectations on the quality or results of such work programs are subject to risks associated with operations on the property, exploration activity generally, equipment limitations and availability, as well as other risks that we may not be currently aware of. Accordingly, readers are advised not to place undue reliance on forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information, whether as a result of new information, future events or otherwise. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289584 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ANTWERPEN, BELGIUM, Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - This marks the 11th time the company has been recognized as a Leader. OMP believes this recognition underscores its consistent delivery of innovative solutions such as UnisonIQ and Unison Decision-Centric Planning. It reflects a market shift toward AI-driven supply chain planning, and the growing demand for platforms that unify strategy, execution, and intelligence in real time.Advancing intelligent planning for the most complex supply chain needsTrusted by Fortune 500 leaders such as AstraZeneca, BASF, Johnson & Johnson, and Procter & Gamble, OMP continues to advance supply chain planning through Unison Planning™, its proven end-to-end platform. Open, cloud-native, and AI-driven, the platform is built to meet the evolving demands of process and discrete global supply chains, including chemicals, consumer goods, life sciences, paper and packaging, tires and building products, and metals.Unison Planning™ incorporates UnisonIQ, OMP's AI orchestrator that unifies AI agents, assistants, and engines into one powerful framework. Designed for the agentic age of supply chain planning, UnisonIQ embeds continuous intelligence throughout the platform, giving organizations a foundation for proactive, autonomous decision-making grounded in deep industry expertise."Agentic AI is fundamentally reshaping how supply chains operate and compete," says Paul Vanvuchelen, Chief Executive Officer at OMP. "Organizations that embrace this shift will turn volatility into strategic advantage."Accelerating decision velocity for the entire supply chainOMP's Unison Decision‑Centric Planning elevates supply chain performance by uniting human expertise, advanced AI, real‑time intelligence, and rapid scenario evaluation to drive decision velocity and improve decision quality across the enterprise."With comprehensive supply chain intelligence and AI-powered anticipation, Unison Decision-Centric Planning enables organizations to gain earlier visibility into disruption, evaluate its impact, and prepare the next move with clarity and confidence," says Philip Vervloesem, Chief Commercial & Markets Officer at OMP.About the Gartner Magic QuadrantThe 2026 Gartner Magic Quadrant for Supply Chain Planning Solutions: Process Industries, released in March 2026, evaluates vendors based on their Ability to Execute and Completeness of Vision, helping global companies identify the right partners in a complex and fast-evolving market.We believe this recognition comes alongside OMP's strong performance in the 2026 Gartner Critical Capabilities for Supply Chain Planning Solutions Process Industries report, where it had been ranked in the highest two positions across all Use Cases. OMP also continues to receive strong customer ratings on Gartner Peer Insights™, reflecting positive feedback from enterprise users.For more information about OMP's position as a Leader in the Gartner Magic Quadrant and the future of supply chain planning, read the full report.Meet OMP at the Gartner Supply Chain Symposium/Xpo™OMP will participate in the 2026 Gartner Supply Chain Symposium/Xpo™, where customers will share practical insights on intelligent, decision-centric supply chains:Procter & Gamble will present key learnings from its collaboration with OMP at the Symposium/Xpo™ US, highlighting how integrated planning and end-to-end visibility drive measurable business impact.AstraZeneca will present its journey toward decision-centric autonomous planning at the Symposium/Xpo™ EMEA, highlighting how it is transforming processes and capabilities to achieve excellence.About OMPOMP helps companies facing complex planning challenges to excel, grow, and thrive by offering the best digitized supply chain planning solution on the market. Hundreds of customers in a wide range of industries - spanning consumer goods, life sciences, chemicals, metals, paper, plastics & packaging, tires and building products - benefit from using OMP's unique Unison Planning™.Gartner, Magic Quadrant for Supply Chain Planning Solutions, Pia Orup Lund, Joe Graham, Buse Aras, Jan Snoeckx, Eva Dawkins, Julia von Massow, 18 March 2026.Gartner, Critical Capabilities for Supply Chain Planning Solutions: Process Industries, Julia von Massow, Eva Dawkins, Jan Snoeckx, Buse Aras, Joe Graham, Pia Orup Lund, 18 March 2026.Gartner and Magic Quadrant are trademarks of Gartner, Inc., and/or its affiliates.Gartner does not endorse any company, vendor, product or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner's business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose.Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.Solution and product inquiriesContact OMPMedia inquiriesKira Perdue (Carabiner)SOURCE: OMP Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TAMPA, FLA., Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - Wellgistics Health, Inc. ("Wellgistics" or the "Company") (NASDAQ:WGRX) today announced that it has entered into a non-exclusive, non-binding Letter of Intent ("LOI") to evaluate a potential acquisition of Neuritek Therapeutics, a neuroscience-focused research organization.The proposed all stock transaction, if completed, is intended to enhance Wellgistics' existing revenue-generating healthcare platform by expanding capabilities adjacent to its core technology-enabled pharmacy distribution and services business. Through its integrated ecosystem spanning prescription fulfillment, wholesale distribution, and AI-driven patient access solutions, Wellgistics connects manufacturers, providers, and a nationwide network of independent pharmacies. The Company believes that adding a research-focused organization could strengthen alignment between drug development and commercialization, enabling earlier engagement with pharmaceutical partners, improving pipeline visibility, and supporting incremental revenue opportunities while enhancing long-term shareholder value through a more integrated and differentiated platform.The transaction remains subject to the completion of due diligence, negotiation and execution of definitive agreements, approval by the boards of directors of the respective parties, and other customary closing conditions. There can be no assurance that a definitive agreement will be entered into or that the proposed transaction will be consummated on the terms currently contemplated, or at all. The LOI is non-binding and does not obligate either party to complete the proposed transaction. The scope, structure, and terms of any potential transaction remain under evaluation and may change materially as a result of ongoing diligence and negotiations.The Company is also actively evaluating additional strategic opportunities across the healthcare and life science sectors as part of its broader growth strategy. These opportunities may include acquisitions, partnerships, or other strategic transactions. There can be no assurance that any such initiatives will result in completed transactions.About Wellgistics Health, IncWellgistics Health is a rapidly scaling, technology-driven healthcare platform positioned at the center of pharmaceutical distribution and patient access. The Company has built an integrated, high-performance ecosystem spanning wholesale distribution, prescription fulfillment, and AI-powered access solutions, directly connecting pharmaceutical manufacturers, healthcare providers, and a nationwide network of independent pharmacies.By combining infrastructure, data, and intelligent automation, Wellgistics is executing on a capital-efficient model designed to capture significant share in large and fragmented healthcare markets. The Company is focused on expanding high-margin revenue streams, deepening strategic manufacturer relationships, and driving operating leverage across its platform. With a differentiated end-to-end offering and disciplined execution, Wellgistics is positioned to accelerate growth, enhance earnings visibility, and deliver outsized long-term value for shareholders.About Neuritek Therapeutics Inc.Neuritek Therapeutics Inc. has developed a next-generation bio-mechanism based treatment, treating the root cause of Post-Traumatic Stress Disorder (PTSD). Neuritek's first to market treatment is an orally active inhibitor of fatty acid amide hydrolase type 1 (FAAH1), the enzyme responsible for metabolizing anandamide (AEA) and the first mechanisms-based treatment for PTSD. The company was founded by Doctor William Hapworth MD., a pioneer in clinical research and a practicing psychiatrist with over 30 years' experience.Learn more at www.neuritek.com or join the conversation at LinkedIn, neuritek-therapeutics-incForward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. These forward-looking statements include, without limitation, statements regarding: the potential acquisition of Neuritek Therapeutics, Inc. ("Neuritek"), including the anticipated structure, valuation, timing, and likelihood of completion of any transaction; the preliminary and non-binding nature of the letter of intent; the potential strategic, operational, and financial benefits of any such transaction; the Company's ability to negotiate and enter into definitive agreements; the Company's ability to obtain any required financing; the integration of any acquired business; and the Company's broader growth strategy and future performance.Forward-looking statements may be identified by words such as "may," "could," "would," "should," "expect," "anticipate," "believe," "intend," "plan," "project," "estimate," "potential," "opportunity," "target," "forecast," "continue," "will," and similar expressions.These forward-looking statements are based on current expectations, assumptions, and estimates and are subject to significant risks and uncertainties, many of which are beyond the Company's control. Important factors that could cause actual results to differ materially include, but are not limited to: the risk that the parties do not enter into definitive agreements; the risk that the letter of intent is terminated or does not result in a completed transaction; uncertainties related to the preliminary nature of the proposed valuation and transaction terms, which may change materially; the risk that any required financing is not obtained on acceptable terms or at all; the risk that anticipated benefits of any transaction are not realized; risks associated with integrating a research-focused organization into the Company's existing business; risks related to the development, testing, regulatory approval, and commercialization of pharmaceutical or therapeutic products, including the possibility of unfavorable clinical results or delays; regulatory and compliance risks; and other risks and uncertainties described from time to time in the Company's filings with the U.S. Securities and Exchange Commission.Forward-looking statements speak only as of the date they are made, and undue reliance should not be placed on such statements. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.Wellgistics Media & Investor ContactMedia: media@wellgisticshealth.comInvestor Relations: IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Key Results Highlights:- Revenue Growth: 8.6% increase to approximately HK$1,813.8 million- Net Profit Increase: 3.5% rise to HK$318.1 million, driven by operational efficiency- Final Dividend: Proposed final dividend of HK7.0 cents per share, bringing total dividend for 2025 to HK14.0 cents per share, a 16.7% surge from HK12.0 cents in 2024- Net Cash & Cash Equivalents: HK$782.7 million (HK$557.2 million as at 31st December 2024)Regulatory Milestones:- NMPA Approval: Multi-dose Diquafosol Sodium Eye Drops approved in July 2025; multi-dose Sodium Hyaluronate Eye Drops approved in January 2026 for registration and commercialisation in the PRC- BLA Acceptance: Bevacizumab ophthalmic injection BLA accepted by NMPA in August 2025, marking a crucial regulatory milestoneBusiness Developments:- Exclusive Distribution (Seefunge): Exclusive distribution of Seefunge's Emedastine Difumarate and Oxybuprocaine Hydrochloride Eye Drops in the PRC- Exclusive Distribution (Osteopore): Exclusive distribution of Osteopore’s innovative dental, orthodontic and maxillofacial products in the PRC, Hong Kong and Macau.- Collaboration with Airdoc: Joint operation of Artificial Intelligence-based retinal businesses in the PRC- Strategic Collaboration with Kenvue: Promotion and marketing of Kenvue's consumer health products (Rhinocort(R), Motrin(R), Tylenol(R)) in the PRC.- International Innovation Accelerator: Signed MOU with Suzhou Industrial Park to launch cross-border life sciences accelerator.- First Overseas Market Entry: Beifushu(R) introduced to Singapore via Special Access Route at Singapore National Eye Centre.Intellectual Property and Market Presence:- Robust IP Portfolio: 121 patent certificates or authorisation letters, comprising 91 invention patents, 15 utility model patents and 15 design patents.- Extensive Distribution Network: Products available in over 14,600 hospitals and medical providers, and approximately 2,600 pharmaceutical stores across the PRCAwards and Recognition:- 2025 Top 500 Manufacturing Companies in Guangdong Province: Recognises industrial scale and comprehensive competitiveness- National Manufacturing Champion Enterprise: Affirms leading position in specialized biopharmaceutical segment- 2025 "Golden Kunpeng" China Financial Value Ranking – Most Valuable Listed Company for Investment: Highlights capital market recognition of growth potential- Participation at Asia-Pacific Academy of Ophthalmology Congress 2026: Showcasing key ophthalmology products and pipeline assets, strengthening engagement with regional eye care professionals and institutions.HONG KONG, Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - Essex Bio-Technology Limited (“Essex” and its subsidiary the “Group”, Stock Code: 1061.HK), a leading biologic Group that develops, manufactures and commercialises genetically engineered therapeutic recombinant bovine basic fibroblast growth factor (“rb-bFGF”), today announced robust annual results for the year ended 31st December 2025, with revenue up 8.6% to HK$ 1,813.8 million and net profit up 3.5% YoY to HK$318.1 million. The Group achieved multiple regulatory milestones and expanded its product portfolio through strategic collaborations, and Beifushu’s landmark entry into Singapore. These achievements underscore Essex's commitment to innovation and operational excellence, driving sustained revenue and profit growth.Diversified Growth Fueled by Flagship BiologicsThe Group achieved a consolidated turnover of approximately HK$1,813.8 million, with an increase of 8.6% as compared to approximately HK$1,669.8 million in 2024. Correspondingly, the Group’s profit increased by 3.5% to approximately HK$318.1 million as compared to approximately HK$307.2 million in 2024.The Beifushu(R) series and Beifuji(R) series, the Group’s flagship products drove growth, contributing 83.5% of turnover.The ophthalmology segment (“Ophthalmology”) recorded a turnover of HK$835.0 million, grew 8.2% year-on-year, led by Beifushu(R) unit-dose eye drops and supported by its preservative free design and expanding application scenarios, which cover multiple areas such as dry eye treatment and post-operative recovery, and contributions from Beifushu(R) eye gel, (Iodized Lecithin Capsules) and a range of unit-dose eye drops (Tobramycin, Levofloxacin, Sodium Hyaluronate, Moxifloxacin Hydrochloride and Diquafosol Sodium Eye Drops).The surgical segment (“Surgical”) turnover rose 1.8% year-on-year to HK$895.9 million, leveraging Beifuji’s broad clinical applications across multiple medical departments and strong market presence. It is also supported by numerous clinical guidelines and expert consensus, thereby laying a solid foundation for future indication expansion and sustained growth. In addition, Group Carisolv(R) dental caries removal gel, PELNACTM collagen-based artificial dermis and SCALGENTM double-layered artificial dermis had further strengthened and contributed to the Surgical business.Notably, Healthcare and Partner Services delivered a total turnover of approximately HK$82.9 million for the year ended 31st December 2025, representing a significant increase of 350% as compared to 2024. The growth was primarily driven by Dr. YaDian oral care products, online and offline healthcare services and CMO/CDMO services.Strengthening Financial Position and Shareholder ReturnsThe Group maintains a healthy financial position, with cash and cash equivalents of approximately HK$782.7 million as of 31st December 2025. Bank borrowings stand at HK$325.6 million, with a manageable repayment schedule over 5 years period. The Group’s gearing ratio is at 30.9% (2024: 28.8%), indicating disciplined financial management and ample liquidity.The Board is pleased to propose a final dividend of HK7.0 cents per ordinary share. Together with the interim dividend of HK7.0 cents per ordinary share, the total dividend for 2025 reaches HK14.0 cents, representing a notable year-on-year increase of 16.7% from HK12.0 cents in 2024, demonstrating the Group’s ongoing commitment to delivering greater returns to its shareholders.Broad Portfolio and Robust Pipeline Fuel Sustained GrowthThe Group’s business comprises three core segments: Ophthalmology, Surgical (wound care and healing) and Healthcare and Partner Services segment, with the Group’s six (6) flagship commercialised biologics, collectively referred to as the “bFGF Series”, which are marketed and sold in the PRC. Three of the bFGF Series were approved by NMPA as Category I drugs, and five are listed on the National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance in the PRC.In addition, the Group offers a portfolio of commercialised preservative-free unit-dose eye drops, including Tobramycin, Levofloxacin, Sodium Hyaluronate, Moxifloxacin Hydrochloride and Diquafosol Sodium Eye Drops. The Group further expanded its ophthalmology franchise by obtaining NMPA approvals for the registration and commercialisation of multi-dose Diquafosol Sodium Eye Drops in July 2025 and multi-dose Sodium Hyaluronate Eye Drops in January 2026. The new launches target the PRC’s growing dry eye treatment market, complementing the Group’s Beifushu(R) ophthalmic repair series.As for the Surgical segment, the Group’s Carisolv(R) dental caries removal gel, Portable Ultraviolet Phototherapy Devices, PELNACTM collagen-based artificial dermis, SCALGENTM double-layered artificial dermis and Osteopore’s bioresorbable implants (Osteomesh(R) and Osteoplug(R)), are complementing the Group’s Beifuji(R) wound healing series.Strategic R&D Investment to Capture Emerging Market OpportunitiesThe Group is committed to pragmatically investing in new products and technologies to strengthen its product and R&D pipeline, with a mission to develop groundbreaking therapeutics that address unmet clinical and commercial needs. In 2025, total R&D expenditures were approximately HK$177.2 million, representing 9.8% of the turnover, of which approximately HK$139.3 million were capitalised.During the year, the Group’s Medical Scar Repair Gel obtained NMPA registration approval as a Class II medical device, expanding the Group’s footprint in the fast-growing high-end wound care and medical aesthetics markets, unlocking new growth drivers for long-term success.The global phase 3 clinical project of bevacizumab ophthalmic injection (EB12-20145P) has successfully completed patient enrolment across the PRC, Australia, European Union countries and the United States, with the last patient last visit was completed. A Biologics License Application (BLA) was accepted by NMPA in the PRC in August 2025.To amplify the Group’s presence in the Asia ophthalmic community and accelerate the market launch of new products, the Group participated in the 2026 Asia-Pacific Academy of Ophthalmology (APAO) Congress. The event provided a premium platform to showcase ophthalmic solutions, engage with regional clinical experts and partners, and build momentum for the rollout of its innovative ophthalmic products, reinforcing its global brand influence.The Group holds a total of 121 patent certificates or authorisation letters, comprising 91 invention patents, 15 utility model patents and 15 design patents.The Group currently has multiple R&D sites located in Zhuhai (PRC), Boston (United States), London (United Kingdom) and Singapore. These sites support the Group’s efforts to develop new therapeutics and recruit global talent.To date, the Group has 18 R&D programmes ranging from pre-clinical to clinical stages, with several ophthalmology programs currently in the clinical stage, specifically Bevacizumab intravitreal injection, SkQ1 eye drops and Cyclosporine eye dropsBroadening Commercial Reach Through Market Expansion and PartnershipsAs of 31st December 2025, the Group maintains an extensive network of 47 regional sales offices in the PRC and a strategic base in Singapore to facilitate market access into Southeast Asian countries. With a vast distribution network, the Group’s products are prescribed in more than 14,600 hospitals and medical providers, coupled with approximately 2,600 pharmaceutical stores, covering major cities throughout the PRC.During the year under review, the Group achieved multiple landmark breakthroughs in the PRC and overseas market expansion, unlocking new multi-dimensional growth momentum. In the overseas market, the Group’s flagship product Beifushu(R) was successfully introduced to Singapore via the Special Access Route at the Singapore National Eye Centre, marking the product’s first commercial launch beyond the PRC, and establishing a solid foothold to support the Group’s future expansion into Southeast Asia and global markets.In the PRC market, the Group entered into two landmark strategic partnerships during the year: a collaboration with global consumer health leader Kenvue, under which the Group will leverage its extensive nationwide commercial network in the PRC to carry out promotion, medical education and marketing for Kenvue’s selected consumer health products including Rhinocort(R) (Budesonide Nasal Spray), Motrin(R) (Ibuprofen Suspension/Drops), and Tylenol(R) (Paracetamol Drops/Suspension); and an exclusive distribution agreement for Osteopore’s innovative dental, orthodontic and maxillofacial products in the PRC, Hong Kong and Macau, marking a strategic entry into the high-potential stomatology market. The partnerships broaden the Group’s healthcare business footprint, delivering strong synergies with its existing ophthalmology and regenerative medicine lines.To drive sustainable growth and expansion for its current and future products, the Group has been investing relentlessly in enhancing its competitiveness and broadening its reach by expanding the clinical indications for its commercialised products, increasing patient access in lower-tier cities across the PRC, developing complementary sales channels, and nurturing the healthtech e-platform to enhance patient access.The Group’s second factory at Zhuhai Hi-Tech Industrial Park, with a gross floor area of about 58,000 square meters for R&D, manufacturing, office and dormitory, is expected to complete in the period of 2026 -2027.Mr. Patrick Ngiam, Chairman of Essex, said “2025 was a standout year with Beifushu’s landmark entry into Singapore, driving robust growth through flagship products, innovation-focused R&D, and strategic partnerships. Essex remains committed to addressing unmet needs and driving long-term growth.We will proactively and systematically recalibrate operating and distribution costs to mitigate the negative impact on FY26 profit from the increase of VAT from 3% to 13% without disrupting our focus on Group development plans.”About EssexBio (1061.HK)EssexBio is a bio-pharmaceutical company that develops, manufactures, and commercialises genetically engineered therapeutic b-bFGF, with six commercialised biologics currently marketed in China. Additionally, the Company has a diverse portfolio of commercialised preservative-free unit-dose eye drops, Shilishun (Iodized Lecithin Capsules) and others, which are principally prescribed for wound healing and diseases in Ophthalmology and Dermatology. These products are marketed and sold through approximately 14,600 hospitals, supported by the Company’s 47 regional offices in China. Leveraging its in-house R&D platform in growth factor and antibody technology, EssexBio maintains a robust pipeline of projects in various clinical stages, covering a wide range of fields and indications. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Brisbane, Australia--(ACN Newswire via SeaPRwire.com - March 23, 2026) - Graphene Manufacturing Group Ltd (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that the Company has officially launched its European sales activity. During the week of March 9th, GMG held a kick off training workshop in London where it brought together its new team members from various locations in Europe and UK for technical product and sales training.The GMG European Sales team numbers more than 10 professional sales executives based in Europe and UK who focus on lead generation, inside sales and executive sales business development for GMG's G® Lubricant and THERMAL-XR® products.Figure 1: Members of the GMG European Sales TeamTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/289529_gmg_figure1.jpgSeparately, the Company is also pleased to announce that it has been informed that the G® Lubricant patent in Europe has been accepted to be granted for a period of 20 years.Craig Nicol, CEO & Managing Director of the Company, commented "Building a sales force in key areas of the world is one of GMG's key activities it is focused on right now and to get the European team set up and running so fast has been a great achievement."Jack Perkowski, Chairman and Non-Executive Director of the Company, commented: "I congratulate the Company on building the European Sales team and look forward to hearing of future success."About GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed at improving the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and U.S. securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "believes" "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, the size, term and success of GMG's European sales team and the eventual granting of and successful enforceability of the Company's G® Lubricant patent.Such forward-looking statements are based on a number of assumptions of management, including the European sales team will perform and the Company's G® Lubricant patent will be patented successfully. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation that the GMG European Sales team does not successfully drive sales for the Company and the Company's G® Lubricant patent is not patented and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 4, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289529 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com